Sa083 SYMPTOMATIC IMPROVEMENT WITH VEDOLIZUMAB THERAPY FOR CROHN'S DISEASE STRATIFIED BY DISEASE ACTIVITY AND PRIOR TUMOR NECROSIS FACTOR ANTAGONIST FAILURE: POST HOC ANALYSES FROM THE GEMINI 2 TRIAL

2021 ◽  
Vol 160 (6) ◽  
pp. S-414
Author(s):  
Marla Dubinsky ◽  
Geert R. D'Haens ◽  
Ninfa Candela ◽  
Theresa Peterson ◽  
Sharif M. Uddin ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Tumor Necrosis Factor ◽  
Crohn's Disease ◽  
Disease Activity ◽  
Tumor Necrosis ◽  
Symptomatic Improvement ◽  
Tumor Necrosis Factor Antagonist ◽  
Post Hoc ◽  
Factor Antagonist ◽  
Necrosis Factor

scholarly journals Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

2014 ◽  
Vol 147 (3) ◽  
pp. 618-627.e3 ◽  
Author(s):  
Bruce E. Sands ◽  
Brian G. Feagan ◽  
Paul Rutgeerts ◽  
Jean-Frédéric Colombel ◽  
William J. Sandborn ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Tumor Necrosis Factor ◽  
Crohn's Disease ◽  
Induction Therapy ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Antagonist ◽  
Factor Antagonist ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document